NCT01930045View on ClinicalTrials.gov

A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

December 10, 2013

Study Completion Date

December 10, 2013

Conditions
HIV Infections
Interventions
DRUG

Raltegravir (ISENTRESS™)

Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.

DRUG

MAALOX (MAL)

MAL (or generic equivalent) 20 mL oral single dose on Day 1

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01930045 - A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295) | Biotech Hunter | Biotech Hunter